EMA’s envisaged risk-based and human-centric approach to regulate AI

Published

Sep 15 2023

Written By

As a partner in our Munich team, I advise clients in the life sciences and healthcare sectors on matters at the intersection of IP, unfair competition, and regulatory law. I am a member of our Intellectual Property Practice Group as well as our Life Sciences and Healthcare Sector Group.

Dr. Nils Lölfing

Senior Counsel
Germany

As Senior Counsel in our Technology & Communications Sector Group at Bird & Bird, I provide pragmatic, solution-driven advice on all aspects of data and information technology law. With over a decade of experience as a Tech, AI, and Data Lawyer, I have a strong focus on and extensive expertise in projects involving AI, particularly generative AI, advising clients across a range of industries, including life sciences, healthcare, automotive, and technology.

Hester Borgers

Senior Associate
Netherlands

I am one of Bird & Bird's Life Sciences lawyers, specialising in life sciences regulatory law. I also have a background in complex patent litigation.

Bird & Bird’s international life sciences and healthcare team is at the forefront of the legal developments with regard to AI and the life sciences sector. This article is part of our new series, which will highlight different legal angles to consider when implementing AI in the life sciences and healthcare industry.

Read the full article on BioTalk